JBM (Healthcare) Limited Announces Upcoming Board Meeting to Approve Annual Results and Dividend
Key Points:
- JBM (Healthcare) Limited (Stock Code: 2161) has notified investors of an upcoming board meeting scheduled for Monday, 22 June 2026.
- The meeting will focus on approving the final results for the financial year ended 31 March 2026.
- The Board will also deliberate on the recommendation of a final dividend, if any, for shareholders.
- Other routine business matters may also be transacted during the meeting.
- The announcement was made by YU Chun Kau, Company Secretary, on 5 June 2026.
- The Board comprises a diverse group of executive, non-executive, and independent non-executive directors, including leadership from Chairman and CEO Mr. Sum Kwong Yip, Derek.
Important Information for Shareholders:
- This board meeting is crucial as it will determine the final financial results for the year and the potential final dividend, both of which are highly price-sensitive and could directly impact the company’s share price.
- Investors should note that the announcement of the dividend and the financial results may influence trading activity and valuation, depending on performance and dividend payout.
- Shareholders are advised to monitor the outcome of the board meeting, as the publication of the results and dividend details will provide deeper insights into the company’s financial health and future prospects.
Additional Details:
- The Board includes experienced professionals in both executive and independent roles, which suggests robust governance and oversight of business decisions.
- No other specific price-sensitive developments are disclosed in this announcement, but the final results and dividend recommendation are both events that typically drive share price movements.
- This announcement follows compliance with Hong Kong Stock Exchange regulations, ensuring transparency and timely information to investors.
Disclaimer:
This article is based on the official announcement by JBM (Healthcare) Limited regarding their upcoming board meeting. Investors should note that the actual results and dividend decisions will be made on 22 June 2026 and published thereafter. This information should not be construed as financial advice or a recommendation to buy or sell shares. Please consult your financial advisor before making investment decisions.
JBM（醫療保健）有限公司公布董事會會議日期，將審批年度業績及股息
重點：
- JBM（醫療保健）有限公司（股份代號：2161）已通知投資者，董事會將於 2026年6月22日（星期一）召開會議。
- 會議將重點審批截至 2026年3月31日止財政年度的 最終業績。
- 董事會亦會考慮 建議派發最終股息（如有），回饋股東。
- 會議亦可能處理其他日常業務。
- 公告由 公司秘書余俊球於 2026年6月5日發出。
- 董事會組成多元，包括執行董事、非執行董事及獨立非執行董事，由主席兼行政總裁沈廣業先生領導。
股東需注意的重要資訊：
- 這次董事會會議十分重要，將決定 年度最終財務業績及 最終股息，兩者均屬高度價值敏感事項，可能直接影響公司股價。
- 業績及股息公佈後，根據表現及派息情況，股價或會出現波動。
- 股東應密切留意會議結果，業績及股息細節公佈後，可更深入了解公司財務健康及未來展望。
其他詳細內容：
- 董事會成員具備豐富經驗，治理結構完善，有助審慎決策。
- 公告未有其他具價值敏感的事項，但最終業績及股息建議通常會帶動股價變動。
- 公告遵循香港聯交所規定，確保資訊透明及及時披露。
免責聲明：
本文章根據JBM（醫療保健）有限公司的官方公告編寫。實際業績及股息決定將於2026年6月22日董事會會議後公佈。本文僅供資訊參考，並不構成任何投資建議或買賣指示。請投資者諮詢專業理財顧問作出決策。
